ACOG Practice Bulletin No. 202: Gestational hypertension and Preeclampsia. Obstet Gynecol. 2019;133:e1-e25.
Agency for Healthcare Research and Quality (AHRQ), National Inpatient Sample (NIS 2014).
Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;347:f6564.
Baltajian K, Bajracharya S, Salahuddin S, et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016;215:89.e1-89.e10.
Cantwell R, Clutton-Brock T, Cooper G, et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118:1-203.
Dolea C, AbouZahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. http://who.int/healthinfo/statistics/bod_hypertensivedisordersofpregnancy.pdf Accessed January 8, 2020.
Duhig KE, Shennan AH. Recent advances in the diagnosis and management of pre-eclampsia. F1000Prime Rep. 2015;7:24.
Fingar KR, Mabry-Hernandez I, Ngo-Metzger Q, et al. Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005–2014: Statistical Brief #222. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). 2017. https://www.ncbi.nlm.nih.gov/books/NBK442039/ Accessed January 8, 2020.
Grill S, Rusterholz C, Zanetti-Dällenbach R, et al. Potential markers of preeclampsia--a review. Reprod Biol Endocrinol. 2009;7:70.
Hagmann H, Thadhani R, Benzing T, et al. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem. 2012;58:837-845.
Korvenranta E, Lehtonen L, Rautava L, et al. Impact of very preterm birth on health care costs at five years of age. Pediatrics. 2010;125:e1109-1114.
Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
North RA, McCowan LM, Dekker GA, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875.
Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856-2869.
Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911-919.
Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83:177-181.
Schindler AE. New data about preeclampsia: some possibilities of prevention. Gynecol Endocrinol. 2018;34:636-637.
Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376:631-644.
Uzan J, Carbonnel M, Piconne O, et al. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011;7:467-474.
Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58.e1-8.
Villa PM, Hämäläinen E, Mäki A, et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth. 2013;13:110.
Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PIGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13-22.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Ananth Karumanchi, MD

Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Staff Physician
Cedars-Sinai Medical Center
Los Angeles, California, United States

Disclosures

Disclosure: Ananth Karumanchi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ThermoFisher Scientific
Received grants for clinical research from: Siemens Healthcare Diagnostics Inc.
Owns stock, stock options, or bonds from: Aggamin Therapeutics LLC

Panelists

Sarosh Rana, MD, MPH

Professor of Obstetrics and Gynecology
Section Chief of Maternal-Fetal Medicine
University of Chicago
Chicago, Illinois, United States

Disclosures

Disclosure: Sarosh Rana, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche Diagnostics; ThermoFisher Scientific

Stefan Verlohren, MD, PhD

Professor of Obstetrics and Gynecology
Department of Obstetrics
Charité–Universitäts medizin Berlin
Berlin, Germany

Disclosures

Disclosure: Stefan Verlohren, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals, Inc.; Roche Diagnostics; ThermoFisher Scientific
Served as a speaker or a member of a speakers bureau for: Canon; Roche Diagnostics; ThermoFisher Scientific
Received grants for clinical research from: Roche Diagnostics
Owns stock, stock options, or bonds from: Bayer HealthCare; MSD

Douglas Woelkers, MD

Professor of Maternal-Fetal Medicine
Department of Obstetrics, Gynecology and Reproductive Science
University of California San Diego School of Medicine, United States

Disclosures

Disclosure: Douglas Woelkers, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche Diagnostics
Received grants for clinical research from: Alere Inc.; Roche Diagnostics

Editors

Pakinam Aboulsaoud, PharmD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Carol Smyth, MB

Director, Content Development, Medscape, LLC

Disclosures

Disclosure: Carol Smyth, MB, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / CE

Predict to Prevent: Improving Maternal and Fetal Outcomes Using sFlt‐1/ PlGF Assessment for Preeclampsia

Authors: Ananth Karumanchi, MD; Sarosh Rana, MD, MPH; Stefan Verlohren, MD, PhD; Douglas Woelkers, MD
CME / CE Released: 3/8/2022
Valid for credit through: 3/8/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for OB/GYNs, emergency medicine physicians, nurses, and primary care physicians.

The goal of this activity is to review the available data on the use of sFlt‐1/ PlGF ratio to rule out/in preeclampsia (PE), and to review the clinical applications of these biomarkers in diagnosing PE.

Upon completion of this activity, participants will:

Have greater competence related to
- Appropriately incorporating sFlt‐1/ PlGF assessment into patient evaluation strategies
- Interpreting sFlt‐1/ PlGF data to assess PE risk

Disclosures

Moderator

Ananth Karumanchi, MD

Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Staff Physician
Cedars-Sinai Medical Center
Los Angeles, California, United States

Disclosures

Disclosure: Ananth Karumanchi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ThermoFisher Scientific
Received grants for clinical research from: Siemens Healthcare Diagnostics Inc.
Owns stock, stock options, or bonds from: Aggamin Therapeutics LLC

Panelists

Sarosh Rana, MD, MPH

Professor of Obstetrics and Gynecology
Section Chief of Maternal-Fetal Medicine
University of Chicago
Chicago, Illinois, United States

Disclosures

Disclosure: Sarosh Rana, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche Diagnostics; ThermoFisher Scientific

Stefan Verlohren, MD, PhD

Professor of Obstetrics and Gynecology
Department of Obstetrics
Charité–Universitäts medizin Berlin
Berlin, Germany

Disclosures

Disclosure: Stefan Verlohren, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals, Inc.; Roche Diagnostics; ThermoFisher Scientific
Served as a speaker or a member of a speakers bureau for: Canon; Roche Diagnostics; ThermoFisher Scientific
Received grants for clinical research from: Roche Diagnostics
Owns stock, stock options, or bonds from: Bayer HealthCare; MSD

Douglas Woelkers, MD

Professor of Maternal-Fetal Medicine
Department of Obstetrics, Gynecology and Reproductive Science
University of California San Diego School of Medicine, United States

Disclosures

Disclosure: Douglas Woelkers, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche Diagnostics
Received grants for clinical research from: Alere Inc.; Roche Diagnostics

Editors

Pakinam Aboulsaoud, PharmD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Carol Smyth, MB

Director, Content Development, Medscape, LLC

Disclosures

Disclosure: Carol Smyth, MB, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Ob/Gyn & Women's Health

CME / CE

Predict to Prevent: Improving Maternal and Fetal Outcomes Using sFlt‐1/ PlGF Assessment for Preeclampsia

Authors: Ananth Karumanchi, MD; Sarosh Rana, MD, MPH; Stefan Verlohren, MD, PhD; Douglas Woelkers, MDFaculty and Disclosures

CME / CE Released: 3/8/2022

Valid for credit through: 3/8/2024, 11:59 PM EST

processing....

Earn Credit CME / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Ananth Karumanchi, MD

Panelists

Sarosh Rana, MD, MPH

Stefan Verlohren, MD, PhD

Douglas Woelkers, MD

Editors

Pakinam Aboulsaoud, PharmD

Carol Smyth, MB

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CME / CE

Predict to Prevent: Improving Maternal and Fetal Outcomes Using sFlt‐1/ PlGF Assessment for Preeclampsia

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Ananth Karumanchi, MD

Panelists

Sarosh Rana, MD, MPH

Stefan Verlohren, MD, PhD

Douglas Woelkers, MD

Editors

Pakinam Aboulsaoud, PharmD

Carol Smyth, MB

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Predict to Prevent: Improving Maternal and Fetal Outcomes Using sFlt‐1/ PlGF Assessment for Preeclampsia